Evidence of 68Ga-DOTA-NT-20.3 uptake in pancreatic adenocarcinoma AsPC-1 cell line - in vitro study.

Conclusion New tracer 68Ga-DOTA-NT-20.3 can be a suitable candidate for the clinical use in patients with pancreatic ductal adenocarcinoma.
PMID: 30160211 [PubMed - as supplied by publisher]

Source: Current Pharmaceutical Biotechnology - August 29, 2018 Category: Biotechnology Authors: Marenco M, Lodola L, Persico MG, Frangipane V, Facoetti A, Aprile C, Hodolic M Tags: Curr Pharm Biotechnol Source Type: research